Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Common Equity (2019 - 2025)

Historic Common Equity for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $946.3 million.

  • Kymera Therapeutics' Common Equity rose 597.22% to $946.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $946.3 million, marking a year-over-year increase of 597.22%. This contributed to the annual value of $835.6 million for FY2024, which is 11156.46% up from last year.
  • Kymera Therapeutics' Common Equity amounted to $946.3 million in Q3 2025, which was up 597.22% from $971.5 million recorded in Q2 2025.
  • Kymera Therapeutics' Common Equity's 5-year high stood at $971.5 million during Q2 2025, with a 5-year trough of $258.1 million in Q2 2021.
  • Over the past 5 years, Kymera Therapeutics' median Common Equity value was $483.1 million (recorded in 2021), while the average stood at $569.6 million.
  • Per our database at Business Quant, Kymera Therapeutics' Common Equity skyrocketed by 39343.09% in 2021 and then tumbled by 2288.04% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Common Equity (Quarter) stood at $459.6 million in 2021, then grew by 6.64% to $490.2 million in 2022, then decreased by 19.42% to $395.0 million in 2023, then skyrocketed by 111.56% to $835.6 million in 2024, then rose by 13.24% to $946.3 million in 2025.
  • Its Common Equity was $946.3 million in Q3 2025, compared to $971.5 million in Q2 2025 and $786.2 million in Q1 2025.